Evaluation of Cytotoxic Potentials of Novel Cyclooxygenase-2 Inhibitor against ALL Lymphocytes and Normal Lymphocytes and Its Anticancer Effect through Mitochondrial Pathway

References

• Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. J Lipid Res. 2009;50(Supplement):S29–S34. doi:10.1194/jlr.R800042-JLR200.
   PubMed Web of Science ®Google Scholar
• Prescott SM, Fitzpatrick F. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta. 2000;1470(2):M69–M78. doi:10.1016/s0304-419x(00)00006-8.
   PubMed Web of Science ®Google Scholar
• Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology. 2002;60(1):78–83. doi:10.1016/s0090-4295(02)01637-0.
   PubMed Web of Science ®Google Scholar
• Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007;9(4):210. doi:10.1186/bcr1678.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.025.
   PubMed Web of Science ®Google Scholar
• Saito T, Tamura D, Asano R. Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors. Oncol Rep. 2014;31(4):1637–1644. doi:10.3892/or.2014.3010.
   PubMed Web of Science ®Google Scholar
• Aghvami M, Salimi A, Eshghi P, Zarei MH, Farzaneh S, Sattari F, et al. Targeting the mitochondrial apoptosis pathway by a newly synthesized COX-2 inhibitor in pediatric ALL lymphocytes. Future Med Chem. 2018;10(19):2277–2289. doi:10.4155/fmc-2018-0032.
   PubMed Web of Science ®Google Scholar
• Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci. 2003;24(2):96–102. doi:10.1016/S0165-6147(02)00043-3.
   PubMed Web of Science ®Google Scholar
• Kern MA, Haugg AM, Koch AF, Schilling T, Breuhahn K, Walczak H, et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res. 2006;66(14):7059–7066. doi:10.1158/0008-5472.CAN-06-0325.
   PubMed Web of Science ®Google Scholar
• Sarkar FH, Adsule S, Li Y, Padhye S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem. 2007;7(6):599–608. doi:10.2174/138955707780859431.
   PubMed Web of Science ®Google Scholar
• Liou J-Y, Aleksic N, Chen S-F, Han T-J, Shyue S-K, Wu KK. Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance. Exp Cell Res. 2005;306(1):75–84. doi:10.1016/j.yexcr.2005.01.011.
   PubMed Web of Science ®Google Scholar
• Grösch S, Tegeder I, Niederberger E, Bräutigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001;15(14):2742–2744. doi:10.1096/fj.01-0299fje.
   PubMedGoogle Scholar
• Fu X, Liu W, Huang Q, Wang Y, Li H, Xiong Y. Targeting mitochondrial respiration selectively sensitizes pediatric acute lymphoblastic leukemia cell lines and patient samples to standard chemotherapy. Am J Cancer Res. 2017;7(12):2395–2405.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Camino A, Martin-Guerrero I, García-Orad A. Genetic susceptibility in childhood acute lymphoblastic leukemia. Med Oncol. 2017;34(10):179. doi:10.1007/s12032-017-1038-7.
   PubMed Web of Science ®Google Scholar
• Lengline E, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica. 2013;98(11):e146–e148. doi:10.3324/haematol.2013.095372.
   PubMed Web of Science ®Google Scholar
• Jabbour E, O'Brien S, Ravandi F, Kantarjian H. Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015;125(26):4010–4016. doi:10.1182/blood-2014-08-596403.
   PubMed Web of Science ®Google Scholar
• Zhao J, Lin Q, Song Y, Liu D. Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol. 2018;11(1):132. doi:10.1186/s13045-018-0677-2.
   PubMed Web of Science ®Google Scholar
• Zhao J, Song Y, Liu D. Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. J Hematol Oncol. 2019;12(1):17. doi:10.1186/s13045-019-0705-x.
   PubMedGoogle Scholar
• Wu J, Fu J, Zhang M, Liu D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8(1):104. doi:10.1186/s13045-015-0195-4.
   PubMedGoogle Scholar
• Liu D, Zhao J, Song Y, Luo X, Yang T. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. J Hematol Oncol. 2019;12(1):15. doi:10.1186/s13045-019-0703-z.
   PubMedGoogle Scholar
• Skrtić M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z, et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011;20(5):674–688. doi:10.1016/j.ccr.2011.10.015.
   PubMed Web of Science ®Google Scholar
• Xiao M, Zhang L, Zhou Y, Rajoria P, Wang C. Pyrvinium selectively induces apoptosis of lymphoma cells through impairing mitochondrial functions and JAK2/STAT5. Biochem Biophys Res Commun. 2016;469(3):716–722. doi:10.1016/j.bbrc.2015.12.059.
   PubMed Web of Science ®Google Scholar
• Zarghi A, Naimi-Jamal MR, Webb SA, Balalaie S, Saidi MR, Ipaktschi J. LiClO4-induced Mannich reaction − diastereo- and enantioselective synthesis of β-amino ketones by addition of enamines, imines or silylenolethers to aldehydes and dialkyltrimethylsilylamines. Eur J Org Chem. 1998;1998(1):197–200. doi:10.1002/(SICI)1099-0690(199801)1998:1<197::AID-EJOC197>3.0.CO;2-R.
   Web of Science ®Google Scholar
• Zarghi A, Praveen Rao PN, Knaus EE. Synthesis and biological evaluation of methanesulfonamide analogues of rofecoxib: replacement of methanesulfonyl by methanesulfonamido decreases cyclooxygenase-2 selectivity. Bioorg Med Chem. 2007;15(2):1056–1061. doi:10.1016/j.bmc.2006.10.023.
   PubMed Web of Science ®Google Scholar
• Azami Movahed M, Daraei B, Zarghi A. Synthesis and biological evaluation of new imidazo[1,2-a]pyridine derivatives as selective COX-2 inhibitors. Lett Drug Des Discov. 2016;13(8):793–799. doi:10.2174/1570180813666160613090944.
   Web of Science ®Google Scholar
• T M. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1):55–63.
   PubMed Web of Science ®Google Scholar
• Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature. 1998;391(6662):96–99. doi:10.1038/34214.
   PubMed Web of Science ®Google Scholar
• Liu Q, Sun Q, Liu Y, Zhou L, Zheng N, Liu L. Bioluminescent assay of microbial ATP in postmortem tissues for the estimation of postmortem interval. J Huazhong Univ Sci Technol [Med Sci.]. 2009;29(6):679–683. doi:10.1007/s11596-009-0601-7.
   PubMedGoogle Scholar
• Rotem R, Heyfets A, Fingrut O, Blickstein D, Shaklai M, Flescher E. Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Res. 2005;65(5):1984. doi:10.1158/0008-5472.CAN-04-3091.
   PubMed Web of Science ®Google Scholar
• Berridge MV, Tan AS. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys. 1993;303(2):474–482. doi:10.1006/abbi.1993.1311.
   PubMed Web of Science ®Google Scholar
• Salimi A, Motallebi A, Ayatollahi M, Seydi E, Mohseni AR, Nazemi M, et al. Selective toxicity of persian gulf sea cucumber holothuria parva on human chronic lymphocytic leukemia b lymphocytes by direct mitochondrial targeting. Environ Toxicol. 2017;32(4):1158–1169. doi:10.1002/tox.22312.
   PubMed Web of Science ®Google Scholar
• Sadighara M, Amirsheardost Z, Minaiyan M, Hajhashemi V, Naserzadeh P, Salimi A, et al. Toxicity of atorvastatin on pancreas mitochondria: a justification for increased risk of diabetes mellitus. Basic Clin Pharmacol Toxicol. 2017;120(2):131–137. doi:10.1111/bcpt.12656.
   PubMed Web of Science ®Google Scholar
• Al Maruf A, O'Brien PJ, Naserzadeh P, Fathian R, Salimi A, Pourahmad J. Methotrexate induced mitochondrial injury and cytochrome c release in rat liver hepatocytes. Drug Chem Toxicol. 2018;41(1):51–61. doi:10.1080/01480545.2017.1289221.
   PubMed Web of Science ®Google Scholar
• Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33(S1):79–84. doi:10.1007/s10875-012-9847-0.
   Google Scholar
• Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol. 2010;2010:215158. doi:10.1155/2010/215158.
   PubMedGoogle Scholar
• Liu B, Qu L, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int. 2015;15(1):106. doi:10.1186/s12935-015-0260-7.
   PubMed Web of Science ®Google Scholar
• Tang F, Zhang R, Wang J. Cyclooxygenase-2-mediated up-regulation of mitochondrial transcription factor a mitigates the radio-sensitivity of cancer cells. Int J Mol Sci. 2019;20(5):1218. doi:10.3390/ijms20051218.
   Web of Science ®Google Scholar
• Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94(4):252–266. doi:10.1093/jnci/94.4.252.
   PubMed Web of Science ®Google Scholar
• Dempke W, Rie C, Grothey A, Schmoll H-J. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol. 2001;127(7):411–417. doi:10.1007/s004320000225.
   PubMed Web of Science ®Google Scholar
• Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res. 2003;37:1–24. doi:10.1159/000071364.
   PubMed Web of Science ®Google Scholar
• Fulda S, Debatin K-M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25(34):4798–4811. doi:10.1038/sj.onc.1209608.
   PubMed Web of Science ®Google Scholar
• Norouzi S, Norouzi M, Amini M, Amanzadeh A, Nabiuni M, Irian S, Salimi M. Two COX-2 inhibitors induce apoptosis in human erythroleukemia K562cells by modulating NF-κB and FHC pathways. Daru. 2016;24:1–1. doi:10.1186/s40199-015-0139-0.
   PubMed Web of Science ®Google Scholar
• Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 2010;9(6):447–464. doi:10.1038/nrd3137.
   PubMed Web of Science ®Google Scholar